Figure 1.

The tumor immune response profiles. The tumor microenvironment (TME) from patients prior to ICB exhibit three different immune profiles that correlate with therapeutic efficacy. The first profile is the immune‐inflamed tumor (a). This tumor profile is associated with the infiltration of T cells and myeloid cells within the tumor parenchyma, with immune cell expression of inflammatory cytokines and checkpoint molecules. The second profile is that of the immune‐excluded TME (b). These tumors have immune cells, but these cells are excluded from the tumor hotbeds. The last profile is the immune‐desert tumor (c). This is characterized by the scarcity of tumor‐infiltrating leukocytes and the lack of an immune response. Figure illustration reproduced courtesy of Roche Communications department 105.